Living Cell Technologies Unveils AI Platform for Drug Discovery

Living Cell Technologies Ltd.AU:1AI) has released an update.

Living Cell Technologies Ltd. is set to launch its AlgoraeOS artificial intelligence platform, which predicts drug combinations for diseases by analyzing large amounts of medical data. The platform has already shown promising results in preclinical studies, most notably with AI-116 for dementia, which outperforms standard treatments in cell studies. In addition, the company is conducting preclinical studies for AI-168, a novel drug candidate targeting cardiovascular diseases.

For more insights into AU:1AI stock, check out TipRanks’ Stock Analysis Page.